Posts From the monthly archives: "March 2015"

The total number of novel biomarkers that have come to market in new IVD tests cleared or approved by the FDA over the last 12 years has been very low; an average of just 3 per year*. Is this cause for alarm? At first glance one would assume yes, but the next factor to understand…(Read More)

A study described in a recent paper in the Journal of the National Cancer Institute analyzed the marketing of laboratory-developed tests (LDTs) for cancer by 55 different companies, academic institutions and other organizations. The analysis concludes that a large number of tests are offered without documentation of clinical validation. For example, only half of…(Read More)

PageLines

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access